Nordea Investment Management’s Anika Therapeutics ANIK Stock Holding History

Nordea Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-45,500	Closed	-$2.25M	–	1024
2017 Q2	$2.25M	Sell	45,500 -30,587	-40%	-$1.41M	0.01%	540
2017 Q1	$3.31M	Buy	76,087 +7,337	+11%	+$350K	0.01%	475
2016 Q4	$3.37M	Buy	68,750 +519	+0.8%	+$24K	0.01%	431
2016 Q3	$3.27M	Buy	68,231 +23,831	+54%	+$1.18M	0.01%	396
2016 Q2	$2.38M	Sell	44,400 -1,000	-2%	-$47.1K	0.01%	388
2016 Q1	$2.03M	Sell	45,400 -2,000	-4%	-$81.1K	0.01%	404
2015 Q4	$1.81M	Buy	47,400 +8,900	+23%	+$340K	0.01%	427
2015 Q3	$1.23M	Buy	38,500 +12,700	+49%	+$443K	﹤0.01%	416
2015 Q2	$852K	Buy	25,800 +13,900	+117%	+$496K	﹤0.01%	478
2015 Q1	$490K	Buy	11,900 +1,000	+9%	+$40.4K	﹤0.01%	577
2014 Q4	$444K	Buy	+10,900	New	+$426K	﹤0.01%	595

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Nordea Investment Management's ANIK Position: Q3 2017 in Review

Nordea Investment Management sold out of Anika Therapeutics (ANIK) in Q3 2017, closing a stake of 45,500 shares — an estimated $2.25M sold.

Nordea Investment Management first reported a position in ANIK in Q4 2014 and held it in 11 quarters. The position peaked at $3.37M in Q4 2016. 166 funds tracked by Wall St. Rank hold ANIK as of Q3 2017.

Nordea Investment Management reported no remaining Anika Therapeutics position as of Q3 2017 after selling out during the quarter.
Nordea Investment Management sold 45,500 Anika Therapeutics shares in Q3 2017, an estimated $2.25M.
Nordea Investment Management first reported a position in Anika Therapeutics in Q4 2014 and held it in 11 quarters.
Nordea Investment Management's Anika Therapeutics position peaked at $3.37M in Q4 2016.
166 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2017.

Based on Nordea Investment Management's 13F filing for Q3 2017, filed 9 Nov 2017.